Dr John Brown Chairman	John Brown PhD, MBA, FRSE joined BTG in January 2008 as a non-executive director and was appointed Chairman in March 2008. He is Chairman of the Nomination Committee. John is a non-executive director of a number of public and private biotech companies including Axis-Shield plc and Vectura Group plc. He is Chairman of CXR Biosciences Ltd, chairs the Roslin Foundation and is a non-executive director of the Technology Strategy Board. Until late 2003, John was Chief Executive of Acambis plc. He is an Honorary Professor of Edinburgh University and is a Fellow of the Royal Society of Edinburgh.
Dr Louise Makin Chief Executive Officer	Louise Makin joined BTG as Chief Executive Officer in October 2004. From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998. She is a non-executive director of Premiere Foods plc. Louise has an MBA, and holds an MA in Natural Sciences and a PhD in Metallurgy from the University of Cambridge.
Rolf Soderstrom Chief Financial Officer	Rolf Soderstrom, BA, ACA,  joined BTG as Chief Financial Officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007. From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the USA. From 2000 he was a Director of Corporate Finance at Cable & Wireless plc. Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of PricewaterhouseCoopers after qualifying as a Chartered Accountant.
Professor Colin Blakemore Non-executive director	Colin Blakemore joined BTG as a non-executive director in October 2007 and is a member of the Remuneration and Audit Committees. Colin Blakemore, FMedSci, Hon FIBiol, Hon FRCP, FRS, has been a Professor in the Medical School at Oxford University since 1979. He was Chief Executive Officer of the Medical Research Council from 2003 to 2007, and from 1996-2003 he was Director of the MRC Centre for Cognitive Neuroscience at Oxford. He is a past President of the British Neuroscience Association, the Physiological Society, the Biosciences Federation and the British Association for the Advancement of Science. Colin studied Medical Sciences at Cambridge and completed a PhD at the University of California in Berkeley.
Peter Chambré Non-executive director	Peter Chambré joined BTG as a non-executive director in September 2006.  He is a member of the Nomination and Remuneration Committees. Peter Chambré was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its recent acquisition by AstraZeneca plc. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc. He is Chairman of Axellia Pharmaceuticals AS and of ApaTech Ltd. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company, and Chairman of 7TM Pharma A/S, a Danish biotech company.
Dr William Jenkins Non-executive director	William Jenkins joined BTG as a non-executive director in 2002 and is a member of the Audit and Remuneration Committees. William Jenkins was previously Head of Clinical Development & Regulatory Affairs for Novartis Pharma AG having held the same position pre-merger from 1992 with CIBA-Geigy AG. Prior to that he was Head of Global Clinical Research at Glaxo from 1988. Since 1999 he has been a consultant to pharmaceutical companies and to investment companies in the life sciences sector. He is a member of the Boards of Eurand Pharmaceutical Holdings B.V. and Monogram Biosciences, Inc. He gained MA and MD degrees from the University of Cambridge and his earlier career was in medical research at the Royal Postgraduate Medical School and later as a Senior Lecturer at the Royal Free Hospital, London University.
Giles Kerr Non-executive director	Giles Kerr joined BTG as a non-executive director in October 2007 and is Chairman of the Audit Committee and a member of the Nomination Committee. Giles Kerr is currently the Director of Finance with the University of Oxford, UK . He is also a Director of Victrex plc, Isis Innovation Ltd adn Elan Corporation plc. Previously Giles was the Group Finance Director and Chief Financial Officer of Amersham plc, acquired by GE Healthcare in 2004. Prior to his role at Amersham, he was a partner with Arthur Andersen in the UK. He is a graduate of the University of York and a Fellow of the Institute of Chartered Accountants in England and Wales.
William James O'Shea Non-executive director	Jim O’Shea joined BTG as a non-executive director of BTG in April 2009. From 2007 to 2008, he was Vice Chairman of Sepracor, Inc, where he was also President and Chief Operating Officer from 1999 to 2007. Previously Jim was Senior Vice President of Sales & Marketing and Medical Affairs for Zeneca Pharmaceuticals (US), a business unit of Zeneca Inc. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing in the US and UK. Jim is a Director of Surface Logix Inc and of NASDAQ listed Penwest Pharmaceuticals Co and CombinatoRx Inc. He is also a past Chairman of the US National Pharmaceuticals Council.